Related Experiment Video

Updated: Mar 12, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

New strategies for targeting drug combinations to overcome mutation-driven drug resistance

Linyan Wang1, Haiyun Wang2, Dongli Song1

  • 1Zhongshan Hospital Institute of Clinical Science, Fudan University, Shanghai Institute of Clinical Bioinformatics, Biomedical Research Center, Shanghai, China.

Seminars in Cancer Biology
|November 15, 2016
PubMed

Insights

Targeted cancer therapies face resistance. This review explores drug resistance mechanisms and highlights targeted drug combinations and omics technologies to overcome resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Background:

  • Targeted therapies offer promise for mutation-driven cancers.
  • Drug resistance, both primary and acquired, limits treatment efficacy.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To review mechanisms of drug resistance in targeted cancer therapy.
  • To explore strategies for overcoming drug resistance, focusing on drug combinations.
  • To highlight the role of omics technologies in designing effective combination therapies.

Main Methods:

  • Literature review of drug resistance mechanisms.
  • Analysis of targeted drug combination strategies.
  • Discussion of omics technologies (functional genomics, pharmacogenomics, CRISPR-Cas9 screening) for resistance analysis.

Main Results:

  • Identified key mechanisms of primary and acquired drug resistance.
  • Proposed targeted drug combinations as a strategy to minimize resistance.
  • Emphasized the utility of omics data in designing combination therapies.

Conclusions:

  • Drug resistance remains a significant challenge in targeted cancer therapy.
  • Combination therapies, guided by omics data, offer a promising approach to overcome resistance.
  • Pathway-centric therapies may improve patient prognosis by addressing heterogeneity.
Keywords:
CRISPR-Cas9 screeningDrug resistanceLung cancerPathway-centric therapyPharmacogenomics profilePrecision medicine

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61